Moomoo AI 已提取核心信息
Heart Test Laboratories, Inc. held its 2024 Annual Meeting of Shareholders on January 17, 2024, where shareholders voted on various proposals. However, Proposal 7, which sought to amend the Company's Certificate of Formation to decrease the number of shares required for a quorum at shareholder meetings, did not receive enough proxies to pass. Consequently, the meeting was adjourned, leveraging Proposal 8 which allows for adjournment to solicit additional proxies. The reconvened meeting is scheduled for February 15, 2024, and will be conducted via live audio webcast. Shareholders do not need to resubmit their proxies if they have already voted, and the votes will be counted at the reconvened meeting unless revoked. The record date for shareholder eligibility remains November 20, 2023. Heart Test Laboratories has hired Advantage Proxy...Show More
Heart Test Laboratories, Inc. held its 2024 Annual Meeting of Shareholders on January 17, 2024, where shareholders voted on various proposals. However, Proposal 7, which sought to amend the Company's Certificate of Formation to decrease the number of shares required for a quorum at shareholder meetings, did not receive enough proxies to pass. Consequently, the meeting was adjourned, leveraging Proposal 8 which allows for adjournment to solicit additional proxies. The reconvened meeting is scheduled for February 15, 2024, and will be conducted via live audio webcast. Shareholders do not need to resubmit their proxies if they have already voted, and the votes will be counted at the reconvened meeting unless revoked. The record date for shareholder eligibility remains November 20, 2023. Heart Test Laboratories has hired Advantage Proxy to aid in proxy solicitation for the reconvened meeting, with a base fee of $5,500 plus expenses. Approval of Proposal 7 requires a majority vote from the combined class of common stock and common stock issuable upon conversion of Series C Preferred Stock. Abstentions and broker non-votes will count as votes against the proposal, and without direct instructions from shareholders, brokers cannot vote on this non-routine item.
Heart Test Laboratories, Inc. 于2024年1月17日举行了2024年年度股东大会，股东们对各种提案进行了投票。但是，旨在修改公司成立证书以减少股东大会法定人数所需的股份数量的提案7没有获得足够的代理通过。因此，会议休会，利用第8号提案，该提案允许休会以征集更多代理人。重新召开的会议定于2024年2月15日举行，将通过网络直播进行直播。如果股东已经投票，则无需重新提交代理人，除非被撤销，否则选票将在重新召开的会议上进行计票。股东资格的记录日期仍为2023年11月20日。心脏测试实验室已聘请Advantage Proxy协助为续会的代理人招标，基本费用为5,500美元，外加费用。第7号提案的批准需要C系列优先股转换后可发行的普通股和普通股合并类别的多数票。弃权票和经纪人不投票将计为反对该提案的票，如果没有股东的直接指示，经纪人不能对这个非常规项目进行投票。
Heart Test Laboratories, Inc. 于2024年1月17日举行了2024年年度股东大会，股东们对各种提案进行了投票。但是，旨在修改公司成立证书以减少股东大会法定人数所需的股份数量的提案7没有获得足够的代理通过。因此，会议休会，利用第8号提案，该提案允许休会以征集更多代理人。重新召开的会议定于2024年2月15日举行，将通过网络直播进行直播。如果股东已经投票，则无需重新提交代理人，除非被撤销，否则选票将在重新召开的会议上进行计票。股东资格的记录日期仍为2023年11月20日。心脏测试实验室已聘请Advantage Proxy协助为续会的代理人招标，基本费用为5,500美元，外加费用。第7号提案的批准需要C系列优先股转换后可发行的普通股和普通股合并类别的多数票。弃权票和经纪人不投票将计为反对该提案的票，如果没有股东的直接指示，经纪人不能对这个非常规项目进行投票。
有用
没用